Bioventus, a leader in orthobiologic solutions, announced its entry into the patient care market in Taiwan with the launch of Durolane, a single-injection joint-fluid osteoarthritis (OA) treatment based on a natural, safe and proven technology process called NASHA which yields stabilized hyaluronic acid (HA).
Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. In Taiwan, Durolane is indicated for the treatment of mild to moderate (OA) of the knee.
“The combination of a leading OA solution like Durolane and Taiwan’s robust economy gives Bioventus a terrific opportunity to establish itself and grow in this market,” said Tony Bihl, CEO, Bioventus. “Orthobiologic solutions from Bioventus are now available in six countries in the Asia Pacific region and we plan to build on this as we continue our international expansion.”
“In Taiwan, Bioventus will be working with Eulogiums, a sales and marketing leader with more than 20 years of experience in orthopaedics,” said Isabelle Levy-Unger, managing director International, for Canada, Latin America and Asia Pacific, Bioventus.
“The company’s market coverage, relationships with key opinion leaders, along with its keen understanding of markets and trends made it the natural choice to help us introduce Durolane to patients with knee OA,” she added.
"We believe that only knee OA products with superior quality can withstand in the competitive market in Taiwan and we have confidence that Durolane is the one," said Kenny Liu, CEO, Eulogiums Co Ltd.
Bioventus will continue to work with the current network of distributors carrying the BioStructures product portfolio and expand that sales footprint to bring these solutions to more surgeons and hospitals throughout the US.